Electrolyte Disorders in Prediabetics and in Patients With Type 2 Diabetes Mellitus

Sponsor
Assiut University (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05791188
Collaborator
(none)
200
13

Study Details

Study Description

Brief Summary

The aim of the study is to assess serum sodium [Na+], potassium [K+] magnesium [Mg2+], calcium [Ca2+], and chloride [Cl-] levels in patients who are prediabetic, diabetics and diabetic with complications (Diabetes mellitus type 2)

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    Diabetes mellitus is a chronic disease that imposes enormous socioeconomic burdens attributable to complications of various bodily systems. Diabetes affected 463 million people (9.3% of all people) in 2019 and will affect 700 million (10.9%) by 2045.

    According to the International Diabetes Federation (IDF), the prevalence of diabetes mellitus among Egyptian adults is 15.2%, which may be an underestimation. Therefore, diabetes mellitus should be thoroughly explored in terms of its risk factors, prevention, treatment, and consequences. Moreover, the general population should be aware of and well informed about all aspects of diabetes.

    Prediabetes is a precursor before the diagnosis of diabetes mellitus. Adults with prediabetes often may show no signs or symptoms of diabetes but will have blood glucose levels higher than normal. The normal blood glucose level is between 70 - 99 mg/dL. In patients with prediabetes, the blood glucose levels elevated between 110 - 125 mg/dL.

    Once the patient is diagnosed as prediabetes, he should be checked for progression to type 2 diabetes every one to two years. So early detection of prediabetes and so lifestyle changes through improved nutrition and physical activity are the first line treatment for preventing the transition from prediabetes to diabetes which can be as high as 70%.

    A normal HbA1C level is below 5.7%, a level of 5.7-6.4% indicates prediabetes, and a level of 6.5% or more indicates diabetes. Within the 5.7-6.4% prediabetes range, the higher HbA1C, the greater risk is for developing type 2 diabetes.

    Serum electrolytes are important cofactors for multiple enzymes and play a pivotal role in many key biological and physiological processes, including glucose metabolism. The excess or deficiency of these electrolytes was found to be linked to deleterious metabolism status.

    Diabetic patients frequently develop a constellation of electrolyte disorders. These disturbances are particularly common in decompensated diabetics, especially in the context of diabetic ketoacidosis or nonketotic hyperglycemic hyperosmolar syndrome.

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    200 participants
    Observational Model:
    Case-Control
    Time Perspective:
    Cross-Sectional
    Official Title:
    Electrolyte Disorders in Prediabetics and in Patients With Type 2 Diabetes Mellitus
    Anticipated Study Start Date :
    May 1, 2023
    Anticipated Primary Completion Date :
    May 1, 2024
    Anticipated Study Completion Date :
    Jun 1, 2024

    Arms and Interventions

    Arm Intervention/Treatment
    1- Prediabetics

    Prediabetics who will be diagnosed by: Glycated hemoglobin (HbA1C) test 5.7 - 6.4% % on two separate tests Fasting blood sugar test 110-125 mg/dL (6.1 - 6.9 mmol/L) on two separate tests. Glucose tolerance test 140 - 179 mg/dL (7.8 - 9.9 mmol/L)

    2- Diabetic patients without complications

    Patients with Type 2 diabetes who will be diagnosed by: Glycated hemoglobin (HbA1C) test ≥ 6.5% on two separate tests Fasting blood sugar test ≥ 126 mg/dL (7 mmol/L) on two separate tests Glucose tolerance test ≥ 200 mg/dL (11.1 mmol/L) Random blood sugar test ≥ 200 mg/dL (11.1 mmol/L)

    3- Diabetic patients with complications

    Diabetic patients with complications (nephropathy, neuropathy, cardiovascular, retinopathy, metabolic disorders, diabetic ketoacidosis)

    4- Controls

    apparently normal subjects who have matched age and sex with patients groups

    Outcome Measures

    Primary Outcome Measures

    1. Serum sodium [baseline]

      assessment of serum sodium [Na+] in prediabetic and diabetic patients compared with controls

    2. Serum potassium [baseline]

      assessment of serum potassium [K+] in prediabetic and diabetic patients compared with controls

    3. Serum magnesium [baseline]

      assessment of serum magnesium [Mg2+] in prediabetic and diabetic patients compared with controls

    4. Serum calcium [baseline]

      assessment of serum calcium [Ca2+] in prediabetic and diabetic patients compared with controls

    5. Serum chloride [baseline]

      assessment of serum chloride [Cl-] in prediabetic and diabetic patients compared with controls

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 75 Years
    Sexes Eligible for Study:
    All
    Inclusion Criteria:
    • Patients with prediabetes who will be diagnosed by:

    • Glycated hemoglobin (HbA1C) test (6.1 - 6.4%) on two separate tests

    • Fasting blood sugar test 110-125 mg/dL (5.6 - 6.9 mmol/L) on two separate tests.

    • Glucose tolerance test 140 - 179 mg/dL (7.8 - 9.9 mmol/L)

    • Patients with Type 2 diabetes who will be diagnosed by:

    • Glycated hemoglobin (HbA1C) test ≥ 6.5% on two separate tests

    • Fasting blood sugar test ≥ 126 mg/dL (7 mmol/L) on two separate tests

    • Glucose tolerance test ≥ 200 mg/dL (11.1 mmol/L)

    • Random blood sugar test ≥ 200 mg/dL (11.1 mmol/L)

    • Patients with diabetic complications (nephropathy, neuropathy, cardiovascular, retinopathy, metabolic disorders, diabetic ketoacidosis)

    Exclusion Criteria:

    • Patients with Type 1 diabetes

    Contacts and Locations

    Locations

    No locations specified.

    Sponsors and Collaborators

    • Assiut University

    Investigators

    • Study Director: Mohamed Faisal El-Adawy, Lecturer, Assiut University

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Ahmed Mostafa Saad, Doctor, Assiut University
    ClinicalTrials.gov Identifier:
    NCT05791188
    Other Study ID Numbers:
    • Electrolytes Diabetes Mellitus
    First Posted:
    Mar 30, 2023
    Last Update Posted:
    Apr 4, 2023
    Last Verified:
    Mar 1, 2023
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Ahmed Mostafa Saad, Doctor, Assiut University
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Apr 4, 2023